A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer

Palbociclib for HR positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

Study Co-Chairs
Elisabetta Munzone, MD, Milan, Italy
Prof. Stefan Aebi, MD, Lucerne, Switzerland


Statistician
Meredith Regan

Lead Trial Coordinator
Holly Shaw

Trial Coordinator
Meredith Kissel

Data Manager
Adriana Karausch, Meredith Kissel

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email:

This email address is being protected from spambots. You need JavaScript enabled to view it.


Trial Monitors
Giuseppe Achille, Daniela Celotto, Carmen Comune, Lionel Nobs, Mariana Pardo Contreras, Magdalena Sànchez-Hohl 

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Date of Activation
June 25, 2019

Targeted Accrual
400

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login